Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults

BACKGROUND: EMERALD is evaluating the efficacy and safety of switching from bPI + FTC/TDF regimens (control) to D/C/F/TAF 800/150/200/10 mg in virologically suppressed, HIV-1-infected adults. We present Week 48 primary results. METHOD: EMERALD (NCT02269917) is a randomized, active-controlled, open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Orkin, Chloe, Molina, Jean-Michel, Gallant, Joel, Negredo, Eugenia, Gathe, Joseph, Eron, Joseph, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Opsomer, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631339/
http://dx.doi.org/10.1093/ofid/ofx180.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631339/
http://dx.doi.org/10.1093/ofid/ofx180.009

Ejemplares similares